Intra-Cellular Therapies, Inc.
ITCI
Kedudukan dalam Saham
#1685
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on... Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on creating innovative treatments for conditions affecting the brain and nervous system. The company achieves this by targeting the intricate cellular communication pathways within the central nervous system, primarily operating in the United States. Its commercialized product is CAPLYTA, an approved therapy for schizophrenia in adult patients. Furthermore, the company maintains a robust development pipeline, including lumateperone, which is undergoing late-stage (Phase III) clinical trials for bipolar depression and is also being investigated for autism spectrum disorder and various sleep disturbances associated with neuropsychiatric and neurological illnesses. Other key drug candidates in its pipeline include Lenrispodun (ITI-214), aimed at treating Parkinson's disease and heart failure; ITI-1284-ODT-SL, designed to address neuropsychiatric disorders and behavioral challenges in dementia; and ITI-333, intended for substance use disorders, pain management, and co-occurring psychiatric conditions like depression and anxiety. Established in 2002, Intra-Cellular Therapies, Inc. has its headquarters situated in New York, New York.
Harga Saham
$131.87
Disegerakkan terakhir: 2025-04-02
Modal Pasaran
$12.68B
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Intra-Cellular Therapies, Inc. (ITCI)
Kategori
Healthcare
Pendapatan untuk Intra-Cellular Therapies, Inc. (ITCI)
Pendapatan pada Dec 2024 TTM: $-74.20M
Menurut laporan kewangan terkini Intra-Cellular Therapies, Inc., pendapatan semasa syarikat ialah $-74.20M. Pada tahun 2023, syarikat memperoleh pendapatan sebanyak $-139.04M, peningkatan berbanding pendapatan pada tahun 2022 yang berjumlah $-256.25M. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Intra-Cellular Therapies, Inc. dari 2013 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun | Pendapatan | Ubah |
|---|---|---|
| 2026 (TTM) | $-74.20M | 0.00% |
| 2024 | $-74.20M | -46.63% |
| 2023 | $-139.04M | -45.74% |
| 2022 | $-256.25M | -9.81% |
| 2021 | $-284.12M | 25.17% |
| 2020 | $-226.99M | 53.66% |
| 2019 | $-147.72M | -4.77% |
| 2018 | $-155.13M | 56.96% |
| 2017 | $-98.83M | -14.33% |
| 2016 | $-115.36M | 10.09% |
| 2015 | $-104.79M | 241.45% |
| 2014 | $-30.69M | 14.30% |
| 2013 | $-26.85M | 0.00% |
Pendapatan untuk syarikat atau pesaing serupa
| Syarikat | Pendapatan | Perbezaan Pendapatan | Negara |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | -2,478.01% |
IN
|
